A Policy Shift Driven by Politics, Podcasters, and Emerging Science
Trump administration officials are pushing to make testosterone therapy significantly easier for men to access, aligning federal health policy with the messaging of online influencers and men’s health podcasters — and raising urgent questions about whether the science actually supports such a sweeping change.
Health Secretary Robert F. Kennedy Jr. and Defense Secretary Pete Hegseth are among the senior officials backing the move. On Tuesday, Hegseth announced the military would begin screening troops for low testosterone and offering hormone therapy to help them perform at their “absolute best.” The Food and Drug Administration has already taken concrete steps: last year it removed a prominent safety warning about cardiovascular risks, and last month it proposed rewriting prescribing instructions to permit testosterone use for age-related symptoms such as low libido and erectile dysfunction — conditions not currently covered by the drug’s approved label.
The science here is real, but it is also genuinely incomplete. A decade of new research has strengthened the case for testosterone’s benefits in sexual health and eased some — though not all — concerns about heart risk. What the science does not support is the broader claim, popular among supplement sellers and testosterone clinics, that the hormone functions as a universal cure for fatigue, brain fog, muscle loss, and the general indignities of aging.
What the Research Actually Shows
Cardiovascular Fears Largely Eased
For years, a boxed FDA warning discouraged doctors from prescribing testosterone broadly, citing possible heart risks. That warning is now gone. A major FDA-mandated study published in 2023 followed 5,000 men with a history of heart disease, splitting them evenly between daily testosterone gel and a placebo. After two years, rates of heart attack, stroke, and related cardiovascular events were statistically identical between the two groups. That is a meaningful finding — and it gave regulators the evidence they needed to act.
Sexual Health Benefits Are Real; Other Claims Are Not
A separate series of National Institutes of Health studies, drawing on data from nearly 800 older men, found that testosterone therapy improved erectile dysfunction, libido, and related sexual health measures, and produced modest improvements in mood. It did not meaningfully improve fatigue, memory, or general well-being — precisely the symptoms that dominate online marketing for the hormone. The distinction matters enormously, because it separates evidence-based medicine from commercially motivated hype.
Dr. Shalender Bhasin of Harvard Medical School, who co-led both research efforts and helped write the Endocrine Society’s clinical guidelines, calls the FDA’s proposed label changes “very welcome” and “a big step forward.” He is also clear that the work is far from finished. “There’s a lot more to be done to better define the safety and efficacy,” Bhasin said, noting that the Endocrine Society has formally recommended studies spanning 15 to 20 years to assess slow-developing conditions — prostate cancer chief among them.
The Overprescribing Problem Is Not Hypothetical
The current restrictions exist for a reason. In the early 2010s, pharmaceutical companies poured millions of dollars into television advertising for testosterone gels and patches, marketing them against a sprawling list of symptoms — fatigue, weight gain, brain fog, muscle loss — for which the drugs had no FDA approval. By 2013, testosterone products were generating more than two billion dollars in annual sales. In 2015, the FDA responded with a double correction: manufacturers had to clarify that their drugs were not approved for routine aging complaints, and they had to add a boxed warning about cardiovascular risk.
The prescribing patterns that emerged from that era remain troubling. A study by Michigan researchers found that only 12 percent of men receiving testosterone prescriptions met the Endocrine Society’s clinical criteria — documented symptoms combined with two separate blood tests confirming low hormone levels. That gap between guideline and practice is not a minor administrative footnote. It represents a large population of men receiving a hormone therapy without the diagnostic foundation to justify it.
Dr. Justin Dubin, a urologist at Baptist Health Miami Cancer Institute, has documented similar problems in the telehealth space. A 2022 paper he authored found that only one in seven online prescribing companies asked basic screening questions — including whether a patient planned to have children — and that most companies set no minimum testing threshold for confirming low testosterone before prescribing.
Who Should Not Take Testosterone
Experts are unambiguous on several contraindications. Men who want to have children in the near future should not take testosterone. The hormone suppresses the brain’s signal to the testes, halting natural testosterone production and sperm generation. “It can stop the signal from your brain to your testicles to make testosterone, and so you stop making sperm,” Dubin said. “That can compromise fertility.”
Men with a history of prostate cancer, or who are at elevated risk, face more nuanced guidance that is itself in flux. Most current guidelines recommend careful clinical consideration before prescribing testosterone to this group, given unresolved questions about whether hormone therapy accelerates tumor growth. The FDA’s proposed label update would narrow that caution significantly, restricting it only to men whose prostate cancer has already metastasized — a change that the Endocrine Society’s long-term research recommendations implicitly caution against rushing.
The Telehealth and Supplement Warning
FDA-approved testosterone therapies come in several forms — daily gels and pills, injections and patches lasting weeks, implantable pellets lasting months. Many are now accessible through telehealth platforms, which offer convenience but carry documented risks of inadequate screening, as Dubin’s research makes clear. Dietary supplements marketed online as testosterone boosters occupy an entirely different category: they are not FDA-approved, there is no credible evidence they work, and they should be avoided.
The administration’s push aligns neatly with the cultural politics of masculinity that have defined much of its messaging — and with the financial interests of a testosterone industry that has already demonstrated its willingness to outrun the science. The underlying medical question of how to treat age-related hormonal decline in men deserves serious, evidence-grounded attention. Whether loosening prescribing rules before the long-term data exists is the right way to deliver that attention is a question the science has not yet answered.